maurice cook ( em designs group, inc.) pre-exposure prophylaxis: how to prep with models of men and...
TRANSCRIPT
Mau
rice
Coo
k (E
M D
esig
ns G
roup
, Inc
.)
Pre-ExposureProphylaxis:
How to PrEP with Models of Men and
Women
Robert M Grant,
MD, MPH
Sept 24, 2010
HIV Prevention
• 3 new infections for every person starting ART• Few Concepts Known
– Condoms, Education, Clean Needles, VCT, MTCTp, Circumcision for Heterosexual Men, Treatment
– All underutilized, most controversial
• Multiple Concepts Failed– Acyclovir, Diaphragms, Mass STI Treatment, Intensive
Counseling, Polyanion Microbicides
• No Surrogate Markers Known• Adherence can run ½ reported levels• Potential Beneficiaries
– Would often rather stay in bed then “advocate” for prevention
"We are really groping in the dark"
Salim S. Abdool KarimQuoted in the Washington Post, November 1, 2007
What I Heard(I may have been mistaken)
• Pills are for sick people– We are not sick
• HIV is one of many problems– Certainly NOT the most urgent– Violence, Poverty, Isolation are More Urgent
• If you want to study us– Use our names– Studying sex workers in an era when “sex
work” was a forbidden term was a non-starter
Treatment and PreventionSimilar Technology
• Treatment may prevent transmission
• Prevention enables treatment
• Both may use pills– Indeed, the same pills
• Evaluated with Randomized Clinical Trials– Intention to treat is primary
Prevention is Not Treatment:1) No Patients
• Healthy people, notwithstanding…
• Language That Pathologizes People– “risk groups” and “vulnerable groups” vs– gay men, transexuals, sex workers, etc
• Language that Pathologizes Acts– “risk behavior” vs– Sex or work or community or procreation
Prevention is Not Treatment:2) No regimens
• Treatment regimens can be optimized– In vitro activity suggest target level– Pharmacokinetics suggest dosing interval– Phase II studies narrow to few options– Phase IIb/III select the best option– Phase IV explore alternatives
• Optimization Made possible by – Surrogate markers, small sample size
Prevention is Not Treatment:2) No Regimens
• No surrogate markers for HIV prevention– Immune correlates not known– Minimum protective level not known– Target cells for activity not known– Safety parameters not always clear
• Prevention Trials Are Large – few options evaluated
Counseling When There is No Regimen
• “Adherence” to an optimized regimen – Does not apply to PrEP
• In Prevention, we do not say – “Don’t use condoms unless you can use them
everytime”
• Also Applies to… – Communication with Partners– Use of HIV Tests
• May Apply to Pill use as well.
Prevention is not Treatment3) Drug Resistance?
• In treatment, the virus population has many billions of opportunities to generate resistance– partial adherence to nnRTIs/3TC allows replication to
generate drug resistant mutants– Partial adherence to PIs may not be sufficient to
select the drug resistant mutants.• In Prevention, the virus population clings to a
few mls of genital secretions– it is unknown whether new mutations can be
generated.– Starting PrEP in the window period of infection will
select resistance
Daily PrEP Selected M184I/V Resistance in 2/6 Animals
Garcia-Lerma et al, 2008
Wild type Not testedResistent
Absence of drug resistance in macaques failing iPrEP with oral Truvada (2 weekly doses)
0 4 8 12 16 200
2
4
6
8
0 4 8 12 16 200
2
4
6
8
Log
10 R
NA
cop
ies/
ml 1800 DM91 DM92X
WeeksWeeksWeeks
DK40 DL6V
0 4 8 12 16 200
2
4
6
8
Log
10 R
NA
cop
ies/
ml
0 4 8 12 16 200
2
4
6
8
Weeks0 4 8 12 16 20
0
2
4
6
8
Weeks
wtwt wt
wtwt
0
2
4
6
0 4 8 12 16 20
8
Weeks
wt
Wild type
35032
Not tested
Garcia-Lerma et al, 2009
Resistance and AdherenceConcerns For PrEP
• Starting or Restarting PrEP – during the RNA+/Ab- window”– Expected to select resistance
• Non-adherence to the daily regimen– Unclear effect on resistance– Depends on efficacy, drug levels, selection
• Fear of resistance drives a high bar– People who miss doses may give up– People who miss doses when highly exposed
may be told to give both up (sex and PrEP)
Prevention is Not Treatment:4) We undermine adherence in prevention
These messages have been quoted back to us during qualitative research, as reasons for deferring pill use until efficacy is proven.
Prevention is Not Treatment:5) Synergies expected
• Treatment Choices Are Often Exclusionary– TDF/FTC vs AZT/3TC– EFZ vs NVP– Selecting A means not selecting B
• Prevention Choices Are Typically Complementary– Condom is useful for HIV/ contraception/ STIs– PrEP may protect weak vaccine responses– PrEP may attract people into STI Care
Reported Risk Behavior
Declined With
Open-LabelPost-Exposure
Prophylaxisand
Counseling
Martin et al., AIDS 2004
Air Bags and Seat Belts
• Antagonisms assumed initially, but
• Airbags and seat belt innovations are now motivators for purchase of new cars
• Safety conscious people demand both.
• Synergies Prevail
IMB
I
B
Information Motivation
Skills
Behavior
• Specific IMB for Each Action State• People populated by multiple IMB processes• Condom use, Test Use, PrEP Use, Reporting
IMBot
Oceanic View of Sex and Society
• Dynamic• Complex• Unpredictable• Mysterious• Details matter little• IMBots can learn to
navigate over rough seas• Rough seas are better
avoided than studied
IB
Models of Man
• Herbert Simon(1916-2001)
• Published 1956• “Bounded Rationality”• Not Pathological Within
Social Context• Nobel Prize 1978• APA award 1993
Bounded Rationality and Organizational Decision-making
Organizations. March and Simon, 1958
• Decisions Come From Where People Sit– The Social Situation Governs
• Information availability • Perceptions• Motivation and goals• Learned Skills and Heuristics
Social view of Sexadapted from Gagnon Sexual Conduct 1973
• Sex, both desire and control, are social constructs
• Some safer than others
• Plans may be lost• Behavior
constrained, but not determined.
• Can be studied and understood
I
B
US Traditions in Sex Research
• Kinsey– Biology, Narratives, Outlets
• Sociological (Gagnon & Simon)– Social scripts– Shape both desire and control– National surveys
• Women’s studies/LGBT studies• Development of ED Drugs• AIDS Research
On AIDS Research• John Gagnon• “None of these studies has
been undertaken to understand sexual phenomena, but rather to measure risk of seroconversion and the effectiveness of prevention efforts… Such purely AIDS-driven work forces researchers to follow outbreaks of the epidemic rather than anticipate them.– Disease and Desire. 1989
Community Based Prevention
• Ecuador
• Constitutional Protections for LGBT Communities
• Boston
• Specialized Health Care For LGBT Communities
Both Highly Successful iPrEx Sites
Successful Prevention Initiatives
• Condom Use in US Cities Early 1980s• “Love Carefully” Uganda 1990s• SeroPos Seroadaptive Behaviors Late 1990s• Common Characteristics
– Grass Roots Initiatives– The Scripts Changed
• Love Carefully• Be a rubber man
– Acknowledge Sexual Goals
People Learn What They Need to Know:Will Intermittent PrEP Create a Need to Recognize Exposure and Plan for Sex?
(HPTN 067)
Daily Intermittent
Initiated by Investigators Community
Locus of Control External Internal
Provider as Authority Consultant
Perception Focus Missed Doses HIV Exposure
Desired Behavior Adherence Pill Use
Fostered Social Role Patient Activist
Toward More Effective Prevention
• Advocacy for Study Populations– Gay, Lesbian, Transgender– Sex workers– Drug Users– Discordant couples– Abused
• Focus on Use, not Intention• Turn the Oceans into Roadmaps
– Sex, society, violence, poverty– NIH NIS and CDC NCS?
• Focus on Synergies, not Antagonisms
iPrEx Presentations on PrEP Pill Use
• Lorena Vargas, INMENSA, Lima, Peru– Qualitative Research in Andes
• Albert Liu, SF DPH– Qualitative Research in SF
• Rivet Amico, U. Conn– Next Step Counseling
Many Thanks To
• IPREX Pill Use Working Group– Rivet Amico– Albert Liu– Ed Wolf– Pedro Goicochea– Lorena Vargas– Vanessa McMahan
• Social Approaches– Jeff McConnell– John Gagnon– David Halperin
• HPTN 067 Behavioral Working Group– Frits Von Griensven– Rivet Amico– Kata Chillag– Daniela Marks– Michael Stirrat– Andrew Forsyth– Scott Rose
• Sponsors/Funders– Division of AIDS, NIMH, Gates,
CDC